All In Biotech

Drug Trial Radar · NCT06535607

Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors

A Phase II, Multi-Center Study to Evaluate the Efficacy and Safety of Volrustomig as Monotherapy or in Combination With Anti-cancer Agents in Participants With Advanced/Metastatic Solid Tumors

Last checked: Nov 19, 2026Latest source record: Sep 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 257 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

257

Planned (sponsor's estimate)

Start

Aug 22, 2024

Primary completion

Nov 30, 2028

Study completion Nov 30, 2028

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Aug 2, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

eVOLVE-02 study will evaluate the efficacy and safety of volrustomig as monotherapy or in combination with anti-cancer agents in participants with advanced/metastatic solid tumors.

Conditions

  • Sub-study 1 Cervical Cancer (Volrustomig Monotherapy)
  • Sub-study 2 Head and Neck Squamous Cell Carcinoma (Volrustomig Monotherapy)
  • Sub-study 3 Head and Neck Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy)
  • Sub-study 4 Esophageal Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy)
  • Sub-study 5 Unresectable Pleural Mesothelioma (Volrustomig Monotherapy)

Interventions

  • VolrustomigBiological

    IV Infusion

  • CisplatinDrug

    IV Infusion

  • CarboplatinDrug

    IV Infusion

  • PaclitaxelDrug

    IV Infusion

  • 5-FUDrug

    IV Infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective response rate (ORR)Time frame: Through study completion, an average of 4 years
  2. The number of participants with adverse events/serious adverse eventsTime frame: Through study completion, an average of 4 years

Locations

98 sites in 12 countries. Site status is shown where the registry gives one.

  • Research Site

    Los Angeles, California · Withdrawn

  • Research Site

    Baltimore, Maryland · Recruiting

  • Research Site

    New York, New York · Recruiting

  • Research Site

    Stony Brook, New York · Recruiting

  • Research Site

    Columbus, Ohio · Not yet recruiting

  • Research Site

    Columbus, Ohio · Withdrawn

  • Research Site

    Philadelphia, Pennsylvania · Not yet recruiting

  • Research Site

    Clayton, Australia · Recruiting

  • Research Site

    Nedlands, Australia · Recruiting

  • Research Site

    Ijuí, Brazil · Recruiting

  • Research Site

    Londrina, Brazil · Recruiting

  • Research Site

    Natal, Brazil · Recruiting

  • Research Site

    Porto Alegre, Brazil · Not yet recruiting

  • Research Site

    Santo André, Brazil · Not yet recruiting

  • Research Site

    São Caetano do Sul, Brazil · Recruiting

  • Research Site

    Vitória, Brazil · Recruiting

  • Research Site

    Vitória, Brazil · Not yet recruiting

  • Research Site

    Edmonton, Alberta, Canada · Recruiting

  • Research Site

    Montreal, Quebec, Canada · Recruiting

  • Research Site

    Anyang, China · Not yet recruiting

  • Research Site

    Beijing, China · Not yet recruiting

  • Research Site

    Beijing, China · Recruiting

  • Research Site

    Beijing, China · Active not recruiting

  • Research Site

    Beijing, China · Recruiting

  • Research Site

    Beijing, China · Active not recruiting

  • Research Site

    Bengbu, China · Withdrawn

  • Research Site

    Changchun, China · Withdrawn

  • Research Site

    Changchun, China · Recruiting

  • Research Site

    Changsha, China · Completed

  • Research Site

    Changsha, China · Completed

  • Research Site

    Changsha, China · Active not recruiting

  • Research Site

    Changsha, China · Completed

  • Research Site

    Chengdu, China · Completed

  • Research Site

    Chengdu, China · Active not recruiting

  • Research Site

    Chengdu, China · Recruiting

  • Research Site

    Chongqing, China · Active not recruiting

  • Research Site

    Chongqing, China · Withdrawn

  • Research Site

    Dongguan, China · Active not recruiting

  • Research Site

    Dongguan, China · Recruiting

  • Research Site

    Fuzhou, China · Completed

Showing 40 of 98 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.